Navigation Links
Chemo for Late-Stage Cancer Patients May Be Unjustified
Date:6/9/2011

THURSDAY, June 9 (HealthDay News) -- Some patients with advanced cancer receive drugs that won't help them but could cause them harm, a U.S. study suggests.

University of Chicago researchers analyzed medical and pharmaceutical claims from 1,041 patients with metastatic colon cancer who were treated between January 2007 and June 2010. Of those patients, about one in eight received chemotherapy treatments that weren't supported by evidence from clinical trials or by clinical practice guidelines.

The researchers focused on three specific treatments. One had insufficient data to support its use, one had been shown to be ineffective, and one was not supported by data or a compelling rationale, according to the study.

The treatment with insufficient data involved the use of Avastin (bevacizumab) after a patient's cancer had progressed despite treatment with a combination of the drug and chemotherapy. The treatment shown to be ineffective was Xeloda (capecitabine) after cancer progression while being treated with the same class of drug. The treatment with no compelling rationale was Erbitux (panitumumab/cetuximab) after cancer progression while being treated with similar drugs.

The researchers said the patients who received these treatments were exposed to significant risk without proven benefits at an estimated cost of more than $2 million just for the drugs.

"Patients with advanced cancers that do no respond to standard therapies should either be looking for clinical trials, where there is a chance for benefit, or should have been thinking about shifting toward palliative care," study author Dr. Jonas De Souza, a hematology/oncology fellow, said in a university news release.

"Patients should not face the risks, discomforts and costs of aggressive and often quite toxic chemotherapy with treatment regimens that did not provide a benefit in previous studies," he added.

The study was presented this week at the American Society for Clinical Oncology's annual meeting in Chicago. Experts note that research presented at meetings should be considered preliminary because it has not been subjected to the rigorous scrutiny given to research published in medical journals.

More information

The U.S. National Cancer Institute has more about metastatic cancer.

-- Robert Preidt

SOURCE: University of Chicago, news release, June 6, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tai chi could be key to overcoming cognitive effects of chemotherapy
2. Hormone test predicts ovarian function after chemotherapy for breast cancer
3. Taking Chemo Drug Continuously Delayed Lung Cancers Return
4. After Colon Cancer Surgery, Early Chemo May Pay Off
5. Following colorectal cancer surgery, longer delay before chemotherapy associated with worse survival
6. Antifungal drug delays need for chemo in advanced prostate cancer
7. Many patients fail to properly take oral chemo, leading to complications
8. Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy
9. Chemo Combo May Help Stave Off Pancreatic Cancer Death
10. Genetic information may help predict likelihood of survival following chemotherapy for breast cancer
11. Genomic test shows promise as chemotherapy response, survival predictor for women with breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemo for Late-Stage Cancer Patients May Be Unjustified
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed ... p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed ... pharmaceutical products, garnering increased attention from all stakeholders in the development of new ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a ... closed for the ISE Southeast Awards 2016. Finalists and winners of the ISE® ... Southeast Executive Forum and Awards Gala on March 15, 2016 at the Westin ...
(Date:2/12/2016)... ... ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined Governor Brian Sandoval, ... Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System yesterday to dedicate ... be the first Fisher House in Nevada, and will provide free lodging for families ...
(Date:2/12/2016)... ... , ... Erlanger Agency has announced a new partnership in its ongoing community ... on the fight against breast cancer, fundraising for a local woman named Carmen, who ... Carmen is a loving single mother of two boys who also serves as caregiver ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet ... RDH, and dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s ... professionals, donating their time and skills to help hundreds of uninsured and underinsured people ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 ... Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key Diagnostic ... - Molecular Diagnostics in Genetic Testing. - ... Diagnostics Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
(Date:2/11/2016)... 2016  NOIT™ Research LLC, a private, leading-edge autism ... campaign to assist needy families in obtaining one of ... between February 10, 2016 and March 31, 2016, the ... The NOIT is an auditory stimulus that plays a ... skills. Beth Shier , NOIT Research ...
Breaking Medicine Technology: